PGM2L1 and synovial sarcoma: We then used IHC experiments to validate the expression of these genes in skin biopsies from MF/SS patients, showing that the expression of TOX, DNM3, KLHL42, PGM2L1, and SESN3 was significantly increased in the dermis of SS, advantage-stage MF, and early-stage MF patients compared to that in PE patients and HCs (Figs. 4G, S6A).